Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 142
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT07089706 | A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations | ||
| NCT06655870 | A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants | ||
| NCT04144348 | Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure | ||
| NCT06189053 | A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX) | ||
| NCT04805125 | Immunocompromised Swiss Cohorts Based Trial Platform | ||
| NCT04405076 | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older | ||
| NCT05894525 | Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine | ||
| NCT05533697 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | ||
| NCT04470427 | A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 | ||
| NCT05894499 | Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19 | ||
| NCT04649151 | A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 | ||
| NCT07279766 | Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 | ||
| NCT06880549 | A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors | ||
| NCT07790523 | Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years | ||
| NCT06634797 | A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age | ||
| NCT05894590 | Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19 | ||
| NCT05375838 | A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old | ||
| NCT07561294 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age) | ||
| NCT05995275 | A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age | ||
| NCT05566639 | A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older | ||
| NCT06333704 | Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE | ||
| NCT05280158 | High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients | ||
| NCT05333289 | A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults | ||
| NCT03323398 | Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies | ||
| NCT06067230 | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | ||
| NCT05815498 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19 | ||
| NCT05383560 | Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults | ||
| NCT05972174 | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults | ||
| NCT05366322 | A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults | ||
| NCT04528719 | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive | ||
| NCT05827926 | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults | ||
| NCT05054218 | COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients | ||
| NCT07513376 | A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) | ||
| NCT06508320 | A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) | ||
| NCT05397223 | A Study of Modified mRNA Vaccines in Healthy Adults | ||
| NCT05769621 | A Retrospective Study to Characterize Participants With Propionic Acidemia | ||
| NCT02872025 | Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS) | ||
| NCT05975099 | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | ||
| NCT05127434 | A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age | ||
| NCT06354998 | A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults | ||
| NCT04860297 | A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants | ||
| NCT06097299 | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | ||
| NCT06646406 | Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate | ||
| NCT04064905 | Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults | ||
| NCT05440318 | Use of Wearable Digital Sensors After mRNA Vaccination in Adults | ||
| NCT05415462 | A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | ||
| NCT06305767 | A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) | ||
| NCT05918250 | mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | ||
| NCT03014089 | Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects | ||
| NCT06946225 | ACTengine® IMA203 Combined With mRNA-4203 |
